PSNL
Personalis, Inc. NASDAQ$5.90
Mkt Cap $523.9M
52w Low $3.84
26.9% of range
52w High $11.50
50d MA $7.06
200d MA $7.50
P/E (TTM)
-6.3x
EV/EBITDA
-8.7x
P/B
2.0x
Debt/Equity
0.1x
ROE
-31.1%
P/FCF
-8.9x
RSI (14)
—
ATR (14)
—
Beta
2.21
50d MA
$7.06
200d MA
$7.50
Avg Volume
1.5M
About
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from ti…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -0.31 | -0.26 | +16.1% | 9.03 | -4.7% | +0.3% | +0.3% | -4.0% | -1.1% | -5.2% | — |
| Nov 4, 2025 | AMC | -0.28 | -0.24 | +14.3% | 8.73 | -8.9% | -12.3% | -17.6% | -20.6% | -1.1% | -3.3% | — |
| Aug 5, 2025 | AMC | -0.25 | -0.23 | +8.0% | 5.64 | -26.1% | -21.8% | -19.3% | -20.0% | -20.2% | -19.0% | — |
| May 6, 2025 | AMC | -0.23 | -0.18 | +21.7% | 4.00 | +9.8% | +21.0% | +29.0% | +26.0% | +27.5% | +28.5% | — |
| Feb 27, 2025 | AMC | -0.32 | -0.23 | +28.1% | 4.24 | -5.4% | -2.4% | -3.1% | -3.1% | +5.9% | -0.5% | — |
| Nov 6, 2024 | AMC | -0.33 | -0.64 | -93.9% | 5.58 | -14.0% | -22.6% | -18.5% | -11.8% | -6.3% | -14.9% | — |
| Aug 7, 2024 | AMC | -0.34 | -0.24 | +29.4% | 2.88 | +19.8% | +19.1% | +13.2% | +49.7% | +61.8% | +54.9% | — |
| May 8, 2024 | AMC | -0.44 | -0.26 | +40.9% | 1.57 | +8.9% | +5.1% | +0.0% | -1.9% | -3.2% | -8.9% | — |
| Feb 28, 2024 | AMC | -0.53 | -0.46 | +13.2% | 1.46 | -9.6% | +6.2% | +15.8% | +19.2% | +16.4% | +19.9% | — |
| Nov 7, 2023 | AMC | -0.54 | -0.51 | +5.6% | 0.96 | +15.3% | +21.5% | -2.4% | +5.9% | +11.1% | +22.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.93 | $8.55 | -4.3% | -4.1% | -12.2% | -8.6% | -6.9% | -11.0% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $9.03 | $8.61 | -4.7% | +0.3% | +0.3% | -4.0% | -1.1% | -5.2% |
| Feb 11 | BTIG | Maintains | Buy → Buy | — | $8.62 | $8.54 | -0.9% | +3.2% | -2.7% | -4.8% | -0.6% | +4.4% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $10.17 | $10.28 | +1.1% | +1.9% | +1.5% | -1.8% | -2.0% | -7.9% |
| Jan 9 | BTIG | Maintains | Buy → Buy | — | $8.38 | $8.53 | +1.8% | -3.3% | +2.3% | +4.8% | +11.0% | +14.7% |
| Dec 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.68 | $9.76 | +0.8% | +4.3% | +5.1% | +8.3% | -1.2% | +1.4% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.63 | $8.63 | +0.0% | -2.2% | -7.2% | -11.9% | -13.0% | -13.3% |
| Nov 11 | BTIG | Maintains | Buy → Buy | — | $8.63 | $8.63 | +0.0% | -2.2% | -7.2% | -11.9% | -13.0% | -13.3% |
| Nov 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.63 | $8.63 | +0.0% | -2.2% | -7.2% | -11.9% | -13.0% | -13.3% |
| Nov 11 | Guggenheim | Maintains | Buy → Buy | — | $8.63 | $8.63 | +0.0% | -2.2% | -7.2% | -11.9% | -13.0% | -13.3% |
Recent Filings
8-K
Unknown — 8-K Filing
Dr. Chen received restricted stock upon his appointment, aligning his long-term compensation with shareholder interests and signaling the company views this leadership role as strategically important.
Mar 17
8-K
Personalis, Inc. -- 8-K Filing
Personalis secured milestone Medicare coverage approvals for breast and lung cancer surveillance in Q4 2025, potentially expanding reimbursement and revenue opportunities for its precision oncology genomics platform.
Feb 26
Data updated apr 26, 2026 9:02pm
· Source: massive.com